Teva Reports First Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Teva Reports First Quarter 2016 Results
May 10, 2016 8:04 AM EDT
Piper Jaffray maintained a Neutral rating on Teva Pharma (NYSE: TEVA), and cut the price target to $58.00 (from $59.00), following the company's 1Q earnings report. TEVA reported a non-GAAP EPS of $1.20 on revenues of $4.81B, ahead of the Street's estimates of $1.17 and $4.77B, respectively. Management noted that companies with older, more commodity-focused portfolios should expect... More
May 10, 2016 6:45 AM EDT
Mizuho analyst, Irina Koffler maintained her Buy rating after Teva Pharma (NYSE: TEVA) effectively defended its generics business and eased concerns about the AGN deal closure. A bottom line beat also helped the stock. We think this is a well-managed business and valuation... More
May 9, 2016 7:01 AM EDT
Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.20, $0.03 better than the analyst estimate of $1.17. Revenue for the quarter came in at $4.81 billion versus the consensus estimate of $4.78 billion.
We start 2016 with solid performance across the business, strong financial results and the achievement of several key... More
